Street note, insider bought and position reduced 713% what a flippin moron. Please do as I have done and email the author!
8K- Looks like the CFO is cashing in and cashing out of his options and management is adding a new cash incentive. Typical biotech, they always maximize their personal returns. Shareholders take the risk, management gets a nice salary and options, no need to be pigs. IMO.
yes, it's worse than dog breath for the buyers and holders. It's not so bad for the range traders, or option sellers.
looks like the writing is on the wall there, warning, warning, danger Will Robinson!
there's nothing left to report other than whether, or not the dealers took the over allotment. I think their net price after commission is under $27, so they will probably take the extra shares if the price holds up, but maybe not. They earned a big fee something like $10MM.
large potential market, high risk, they will need to raise cash. LJPC has been a serial loser, money burner, shareholder value destroyer and reverse splitter. I think BB's are an owner now, so you might get a good ride if timed right, but I can't endorse them based on history and lack of DD.
so idiots, or deceivers like you can write deceptive trash posts on the Yahoo MB and earn .05 a post. Get a real job loser!
doubt it, underwriters can't comment for a period of time, I don't recall the exact time restriction.
doubtful, the backers are in the hole and may go ch 11 and then the punks they hire will not get paid.
the timing was fortunate, the broker-dealers did a nice job and earned their high fee. Given all the positives, the insider sales are puzzling. I guess management is just being cautious and conservative. In biotech, anything can happen, good, or bad.
are you nuts, this was a great placement timing by the underwriters. The stock was low $20'sabout 2 weeks ago. I will note, they were well paid for thei work, taking $1.71 per share as an underwriting fee. The net take by the company was $28.5 - the fee, just under $27.
why, nothing material is likely to happen days after an offering. Don't be surprised if there's a pull-back followed by a few weeks of consolidation. Fortunately, the offering size was fairly small and the digestion period should not be too long.
There is no floor on a biotech stock after a huge rise. The people who managed the offering likely sold some stock high and will try to protect the price a little, but they are not going to go crazy. Relax, expect a period of consolidation, invest, or trade accordingly.